Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀº 2023³â 556¾ï 9,000¸¸ ´Þ·¯·Î 2030³â 1,278¾ï ´Þ·¯¿¡ ´ÞÇϰí, ¿¹Ãø ±â°£ µ¿¾È 12.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀº Åõ¿© ½Ã Àüü ¿ë·®À» ºü¸£°Ô ¹æÃâÇÏ´Â Áï½Ã ¹æÃâÇü Á¦Á¦¿Í ´Þ¸®, Àå±â°£¿¡ °ÉÃÄ Á¡ÁøÀûÀ¸·Î Á¶ÀýµÈ ¹æ½ÄÀ¸·Î ¾à¹°À» ü³»¿¡ Åõ¿©ÇÏ´Â µ¥ ÁßÁ¡À» µÐ Á¦¾à ±â¼úÀÔ´Ï´Ù. ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¸ñÀûÀº Ç÷·ù ³» ¾à¹° ³óµµ¸¦ ÀÏÁ¤ÇÏ°Ô À¯ÁöÇϰí, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇϰí, ȯÀÚÀÇ º¹¾à ¼øÀÀµµ¸¦ ³ôÀ̰í, Àüü Ä¡·á È¿°ú¸¦ Çâ»ó½ÃŰ´Â µî ƯÁ¤ Ä¡·á ¸ñÀûÀ» ´Þ¼ºÇÏ´Â °ÍÀÔ´Ï´Ù.
National Health Science°¡ ¹ßÇ¥ÇÑ Åë°è¿¡ µû¸£¸é 2021³â ¿µ±¹¿¡¼ ¾à 117¸¸ ¸íÀÌ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Áø´ÜÀ» ¹Þ¾Æ Àüü Àα¸ÀÇ 1.9%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ½Å°æ°è Áúȯ°ú °°Àº ÁúȯÀÌ º¸Æíȵʿ¡ µû¶ó Áö¼ÓÀûÀ̰í Ç¥ÀûÈµÈ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ȯÀÚÀÇ ¼øÀÀµµ Çâ»ó, Åõ¾à Ƚ¼ö °¨¼Ò, ºÎÀÛ¿ë ÃÖ¼ÒÈ µîÀÇ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¾à¹°ÀÇ ¾ÈÁ¤ÀûÀ̰í Á¦¾îµÈ ¹æÃâÀ» º¸ÀåÇÔÀ¸·Î½á ¸¸¼ºÁúȯÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ ºÎ´ãÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü ¾à¹° ¹æÃâ Á¦¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹æÃâ Á¦¾î ½Ã½ºÅÛÀ» °³¹ß ¹× Á¦Á¶ÇÒ ¶§ º¹ÀâÇÑ ±â¼ú, Ư¼ö Àç·á, ±¤¹üÀ§ÇÑ ¿¬±¸°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Á¦Á¶ ºñ¿ëÀÌ Áõ°¡ÇÕ´Ï´Ù. ±× °á°ú, ÁöºÒÀÚ, ÀÇ·á ½Ã½ºÅÛ, ȯÀÚ ¸ðµÎ°¡ ºñ¿ë Áõ°¡¸¦ ºÎ´ãÇÏ°Ô µË´Ï´Ù. ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÁÙÀÌ´Â µîÀÇ ÀåÁ¡ÀÌ ÀÖÁö¸¸, ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ÀϺΠȯÀÚµéÀº »ç¿ëÇÏÁö ¾Ê¾Æ ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸¸¼ºÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ Àå±âÀûÀÎ ¾à¹° °ü¸®ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ¸¶Âù°¡Áö·Î, ¼Ò¾Æ°ú¿¡¼µµ ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº Á¤È®ÇÑ Åõ¾à°ú ÀæÀº Åõ¾àÀÇ Çʿ伺À» ÃÖ¼ÒÈÇÏ¿© ¾ÈÀü¼º°ú ¼øÀÀµµ¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ±ºÀº ºÎÀÛ¿ëÀ» ÁÙÀ̰í Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇØ °³º°ÈµÇ°í ÀϰüµÈ ¾à¹°Àü´ÞÀ» ÀÚÁÖ ÇÊ¿ä·Î ÇÕ´Ï´Ù. ±× °á°ú, ÀþÀº Ãþ°ú ³ë³âÃþ ¸ðµÎÀÇ Æ¯Á¤ Ä¡·á ¿ä±¸¸¦ ÃæÁ·½ÃŰ´Â ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
±ÔÁ¦ ´ç±¹ÀÇ ±î´Ù·Î¿î ½ÂÀÎÀº ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ß ¹× ÆÇ¸ÅÇÏ·Á¸é ¾ö°ÝÇÑ Å×½ºÆ®¿Í º¹ÀâÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇØ¾ß Çϸç, ÀÌ´Â ½Ã°£°ú ºñ¿ëÀÌ ¸¹ÀÌ ¼Ò¿äµË´Ï´Ù. ÀÌ·¯ÇÑ ½ÂÀÎ Áö¿¬Àº ½ÃÀå ¼ºÀå°ú ±â¼ú Çõ½ÅÀ» ÀúÇØÇϰí ÅõÀÚ¸¦ ¾ïÁ¦ÇÏ¸ç °³¼±µÈ Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.
COVID-19ÀÇ ´ëÀ¯ÇàÀº ¾à¹° ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÆÒµ¥¹Í ±â°£ µ¿¾È ÀǾàǰ°ú Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ¸é¼ ¾à¹° ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß ¹× äÅÃÀ» ÃËÁøÇß½À´Ï´Ù. ±×·¯³ª Àü ¼¼°è °ø±Þ¸ÁÀÇ È¥¶õ, ÀÓ»ó½ÃÇèÀÇ °¨¼Ò, ÀÇ·á ÀÚ¿øÀÇ ÀçºÐ¹è µîÀÌ µµÀü°úÁ¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ·¯½º ÅðÄ¡¸¦ À§ÇÑ ¿¬±¸°³¹ß°ú ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ Çʿ伺¿¡ ´ëÇÑ °ü½ÉÀÌ ÁýÁßµÇ¸é¼ ÀÌ ±â°£ µ¿¾È Á¦¾î ¹æÃâ ±â¼úÀÇ Çõ½Å°ú äÅÃÀÌ °¡¼ÓȵǾú½À´Ï´Ù.
¹æÃâÁ¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå¿¡¼ Ç¥ÀûÀü´Þ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±× ¹è°æ¿¡´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ü³» ƯÁ¤ ºÎÀ§³ª ¼¼Æ÷¸¦ Á¤È®ÇÏ°Ô Å¸°ÙÆÃÇÏ´Â ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¾à¹°Àü´ÞÀº ºÎÀÛ¿ë °¨¼Ò, ¾àÈ¿ °È, ȯÀÚ ¿¹ÈÄ °³¼± µîÀÇ ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷, ±¹¼ÒÀûÀ̰í ÅëÁ¦µÈ ¾à¹° ¹æÃâÀÌ ¸Å¿ì È¿°úÀûÀÎ ¾Ï°ú °°Àº ÁúȯÀÇ Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå¿¡¼ °æ±¸ ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ ºÐ¾ß´Â °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æ±¸ ¾à¹° Åõ¿©´Â Æí¸®ÇÏ°í ºñħ½ÀÀûÀ̱⠶§¹®¿¡ ȯÀÚµéÀÌ ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î º¸´Ù È¿À²ÀûÀÎ °æ±¸ ¹æÃâ Á¦¾î ½Ã½ºÅÛÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í, Åõ¿© Ƚ¼ö¸¦ ÁÙÀ̸ç, Àå±â°£¿¡ °ÉÃÄ ¾ÈÁ¤ÀûÀÎ ¾à¹° ¹æÃâÀ» ½ÇÇöÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
ºÏ¹Ì Áö¿ªÀº ¿¹Ãø ±â°£ µ¿¾È ¾à¹° ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå¿¡¼ ¼±µµÀûÀÎ À§Ä¡¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº Á¦¾à »ê¾÷ÀÌ ¹ß´ÞÇϰí ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ ³ô¾Æ ÷´Ü ¾à¹°Àü´Þ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿Í °·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ±â¼ú Çõ½Å°ú ¹æÃâ Á¦¾î ÀǾàǰÀÇ ½ÂÀÎÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ȯÀÚ Àα¸°¡ ¸¹°í, ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚµéÀÌ Á¸ÀçÇÑ´Ù´Â Á¡µµ ÇâÈÄ ¸î ³â µ¿¾È ÀÌ Áö¿ªÀÇ ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ÀÇ·á Á¢±Ù¼ºÀÌ Çâ»óµÈ Áß»êÃþ Áõ°¡·Î ÀÎÇØ °í±Þ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼´Â ´ç´¢º´ ¹× ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯ÇàÀ¸·Î ÀÎÇØ ´õ ³ªÀº °ü¸®¸¦ À§ÇØ ¹æÃâ Á¦¾î ¾à¹° äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, R&D¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÀÌ Áö¿ªÀÇ Å« ¼ºÀå ÀáÀç·Â¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ Áö¿ªÀº ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Controlled Release Drug Delivery Market is accounted for $55.69 billion in 2023 and is expected to reach $127.80 billion by 2030 growing at a CAGR of 12.6% during the forecast period. Controlled release drug delivery is a pharmaceutical technology focused on administering medications to the body in a gradual and regulated manner over an extended period, in contrast to immediate-release formulations that deliver the entire dose rapidly upon administration. The goal of controlled-release drug delivery systems is to achieve specific therapeutic objectives, such as maintaining consistent drug levels in the bloodstream, minimizing adverse effects, enhancing patient adherence, and improving the overall effectiveness of treatment.
According to statistics published by National Health Science, about 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2021, accounting for 1.9% of the total population.
The controlled release drug delivery market is seeing growth propelled by the escalating prevalence of chronic diseases. With conditions like diabetes, cardiovascular disorders, and neurological ailments becoming more prevalent, there is an increased demand for sustained and targeted drug delivery systems. These technologies offer benefits such as improved patient compliance, reduced dosing frequency, and minimized side effects. By ensuring a steady and controlled release of medications, these delivery systems play a crucial role in managing chronic conditions effectively. As the global burden of chronic diseases continues to rise, the demand for advanced controlled-release drug delivery solutions is expected to expand significantly.
Production costs are increased by the need for complex technologies, specialty materials, and extensive research when developing and manufacturing controlled release systems. As a result, payers, healthcare systems, and patients all bear the increased costs. Although there are benefits associated with controlled release systems, such as better patient compliance and fewer side effects, their higher cost may prevent some patients from using them and thus impede market expansion.
The need for extended medication management to treat chronic health conditions is growing as the elderly population grows. In Similar to this, controlled release systems in pediatrics ensure safety and compliance by offering precise dosing and minimizing the need for frequent administration. To reduce side effects and improve treatment outcomes, these patient groups frequently need individualized, consistent medication delivery. As a result, the market is expanding due to the growing demand for controlled release drug delivery solutions that meet the specific therapeutic needs of both younger and older populations.
Stringent regulatory approvals pose a significant threat to the controlled release drug delivery market. Developing and marketing these advanced drug delivery systems requires rigorous testing and compliance with complex regulatory requirements, which can be time-consuming and costly. Such delays in obtaining approvals can hinder the market's growth and innovation, deterring investment and potentially limiting patient access to improved therapies.
The COVID-19 pandemic significantly influenced the controlled release drug delivery market. The increased demand for pharmaceuticals and antiviral treatments surged during the pandemic, driving the development and adoption of controlled-release drug delivery systems. However, disruptions in the global supply chain, reduced clinical trials, and healthcare resource reallocation posed challenges. Additionally, the focus on research and development to combat the virus and the need for remote patient monitoring accelerated the innovation and adoption of controlled release technologies during this period.
The targeted delivery segment is anticipated to capture the largest market share in the controlled drug delivery market. This prominence is attributed to the growing emphasis on personalized medicine and the need for drug delivery systems that can precisely target specific sites or cells in the body. Targeted delivery offers the advantages of reduced side effects, enhanced drug efficacy, and improved patient outcomes. It is particularly crucial in the treatment of conditions like cancer, where localized and controlled drug release can be highly effective. These factors significantly drive the segment's growth.
In the controlled release drug delivery market, the oral controlled-drug delivery systems segment is anticipated to grow at the highest rate. Patients prefer the oral route of drug administration because it is convenient and non-invasive, which has increased demand for it. Moreover, more efficient oral controlled-release systems have been made possible by continuous improvements in pharmaceutical technology. The market is well-positioned for substantial growth due to its ability to improve patient compliance, lower the frequency of doses, and deliver a consistent release of medications over time.
North America is projected to sustain its leading position in the controlled release drug delivery market during the forecast period. The region has a well-established pharmaceutical industry, a robust healthcare infrastructure, and a high prevalence of chronic diseases, driving the demand for advanced drug delivery technologies. Additionally, substantial investments in research and development, coupled with strong regulatory frameworks, encourage innovation and the approval of controlled-release drug products. The region's large patient population, along with the presence of key market players, contributes to its dominance in the coming years.
The Asia Pacific region is estimated to witness the highest growth in the controlled release drug delivery market during the forecast period owing to the region's rising population, increasing healthcare infrastructure, and a growing middle class with greater access to healthcare, which are driving demand for advanced drug delivery systems. The prevalence of chronic diseases in Asia Pacific, such as diabetes and cancer, is boosting the adoption of controlled-release drugs for better management. Additionally, the increasing investments in research and development contribute to the region's significant growth potential, making it a prominent player in the global market.
Some of the key players in Controlled Release Drug Delivery market include: Abbott Laboratories, Alkermes plc, Aradigm Corporation, Bayer HealthCare LLC, Bracco S.p.A., Bristol-Myers Squibb, Capsugel, Coating Place, Inc., Corium International, Inc., Depomed, Inc., GE Healthcare, GSK plc, Guerbet Group, Johnson and Johnson Ltd., Medtronic AG, Merck and Co.Inc., Mylan N.V., Orbis Biosciences.Inc., Pfizer, Inc., Roche Holding AG, Sanofi, Sino Medical-Device Technology Co., Sun Pharmaceuticals Industries Ltd, Ulrich GmbH & Co. KG and Vectura Group plc.
In April 2023, Researchers at the Indian Institute of Technology Guwahati (IIT-G) have developed liquid marbles using nano clay that can be pre-programmed for drug delivery and cascade chemical reactions. The IIT-G team has used the liquid marbles approach for the controlled release of drugs and programmed chemical reaction. The team has engineered liquid marbles to have a 'time bomb' type release effect and to carry out a spontaneous chemical reaction. The nano clay marbles were made of a shell of nanoclay that holds the liquid. To programme the marbles for timed release of the content, the researchers modified the nanoclay with chemical groups that were either water-loving (hydrophilic) or waterhating (hydrophobic).
In December 2022, InSitu Biologics, Inc. is pleased to announce that it has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.